Patient Resources
Get Healthy!
Results for search "Drug Approvals".
Health News Results - 13
Experimental Alzheimer's Drug Slows Thinking Declines in Late-Stage Trial
- Robin Foster HealthDay Reporter
- July 17, 2023
- Full Page
Another experimental drug meant to slow the damage of Alzheimer's appears poised to join a growing arsenal of new treatments for this memory-robbing disease.
FDA Gives Full Approval to Alzheimer's Drug Leqembi
- Robin Foster HealthDay Reporter
- July 6, 2023
- Full Page
The U.S. Food and Drug Administration on Thursday gave full approval to the Alzheimer's drug Leqembi, clearing the way for insurance coverage of the pricey drug.
"The full FDA approval will open the floodgates for people with early Alzheimer's to get this drug. It's a bi...
FDA Approves New Drugs to Treat Type 2 Diabetes in Kids
- Cara Murez HealthDay Reporter
- June 21, 2023
- Full Page
The U.S. Food and Drug Administration on Tuesday approved two drugs that have been used in adults with type 2 diabetes for years for use in children aged 10 and up.
The approvals of Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) provid...
FDA Approves First Pill to Treat Moderate-to-Severe Crohn's Disease
- Cara Murez HealthDay Reporter
- May 19, 2023
- Full Page
Patients with Crohn's disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).
Rinvoq is meant to treat adults with moderately to severely active Crohn's disease who have not had success with TNF (t...
FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation
- Cara Murez HealthDay Reporter
- May 11, 2023
- Full Page
A medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.
The FDA gave supplemental approval to Otsuka Pharmaceutical Company Ltd., and Lundbeck Inc. for Rexulti (brexpiprazole) oral tablets on Thursday. Rexulti ...
Experimental Alzheimer's Drug Slows Decline in Thinking in Late-Stage Trial
- Cara Murez HealthDay Reporter
- May 3, 2023
- Full Page
Another experimental drug meant for Alzheimer's disease looks so promising that drugmaker Eli Lilly plans to ask the U.S. Food and Drug Administration for full approval by the end of June.
Known as donanemab, the medication clears amyloid plaque from the brain. In a lat...
Could a Vibrating Pill Ease Chronic Constipation?
- Cara Murez HealthDay Reporter
- February 9, 2023
- Full Page
A new treatment for chronic constipation may bring relief without having to use drugs.
It's a vibrating pill called Vibrant that stimulates the colon as it passes through the body.
FDA Approves New 2-Drug Combo Medicine for Asthma
- Cara Murez HealthDay Reporter
- January 12, 2023
- Full Page
Adults with asthma now have a new rescue medication to turn to after the U.S. Food and Drug Administration approved Airsupra on Wednesday.
The drug is the f...
First FDA-Approved Fecal-Based Treatment Helps Fight a Tough Superbug
- Cara Murez HealthDay Reporter
- December 1, 2022
- Full Page
The U.S. Food and Drug Administration on Wednesday approved the first fecal microbiota treatment, aimed at helping adults battling tough-to-treat Clostridium difficile (C. diff) infections.
"Today's approval of Rebyota is an advance in caring f...
A Gene Therapy for Hemophilia That Costs $3.5 Million Gets FDA Approval
- Cara Murez HealthDay Reporter
- November 23, 2022
- Full Page
People with one form of the genetic blood disorder hemophilia now have a one-time treatment with a $3.5 million price tag.
The U.S. Food and Drug Administration approved the new gene therapy Hemgenix on Nov. 22. Soon after, drugmaker CSL Behring revealed its cost.
Hints That Experimental Drug Might Curb a Form of ALS
- By Cara Murez HealthDay Reporter
- September 23, 2022
- Full Page
People with a rare genetic form of ALS may benefit from extended use of an investigational drug, a new study shows.
The medication, tofersen, benefited patients with mutations of the gene SOD1. These mutations create a misfolded version of a protein, which leads to
Merck's COVID Pill Appears Effective, But May Pose Pregnancy Risks: FDA
- Robert Preidt and Robin Foster
- November 29, 2021
- Full Page
Merck's experimental COVID-19 antiviral pill appears effective, but may pose risks for pregnant women, including birth defects and toxicity to developing fetuses, according to the U.S. Food and Drug Administration.